11:35 AM EDT, 05/02/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

We raise our opinion on Smith & Nephew ( SNN ) to Buy from Hold in view of the solid result and the reiteration of guidance, despite the current environment. We raise our target price to USD34 from USD30, which implies 17x our 2025 EPADS estimate. This is above its three-year historical forward P/E of 15.3x, justified by the anticipated recovery from the realization of the 12-Point Plan, in our view. We keep our EPADS estimates of USD2.00 for 2025 and USD2.12 for 2026. Considering its large U.S. manufacturing base (54% of revenue is from the U.S., of which two-thirds is manufactured domestically), we view the company is relatively better equipped to navigate the potential impact of tariffs. We expect growth to be driven by new product launches and productivity improvements from its 12-Point Plan, which is progressing well. We are encouraged to see the return to growth in the U.S. Hip Implants in Q2 2024 and U.S. Knee Implants in Q3 2024 (previously progress was slower-than-expected) with further improvements seen in the Q1 2025.